معرفی
Dr. Lourens Bloem is an Assistant Professor at Utrecht University's Faculty of Science, affiliated with the Division of Pharmacoepidemiology and Clinical Pharmacology under the Utrecht Institute for Pharmaceutical Sciences. He contributes to the Faculty of Science's Open Science Team and previously served as Programme Manager Drug Regulatory Science at Utrecht Science Park until December 2022, leveraging expertise from his 4-year pharmacovigilance assessor role at the Dutch Medicines Evaluation Board (MEB).
- PharmD and MSc in Epidemiology
- Specializes in regulatory science for oncology and rare diseases
- Focuses on real-world evidence and drug lifecycle management
His research bridges clinical pharmacology, oncology, and advanced therapies, examining evidence generation for regulatory decisions, benefit-risk balances, and post-authorization data collection. His applied data science work develops EHR-based algorithms for disease progression tracking in Stage IV NSCLC. Recent publications analyze ATMPs (Advanced Therapy Medicinal Products) regulatory bottlenecks and tumour-agnostic therapies decision-making.
Key article trends include:
- Conditional authorization frameworks (2006-2020)
- Comparative effectiveness of uncontrolled trials
- Environmental impact assessments in drug regulation
- Pharmacovigilance challenges for immunotherapies
- Global pharmacovigilance systems
Lourens collaborates extensively with the European Medicines Agency (EMA), Dutch Cancer Society, and international consortia, contributing to EU pharmaceutical legislation evaluations and sustainable therapy development initiatives like FAST and RSNN SIG Advanced Therapies. He chairs the Future Medicines Graduate Programme's first cohort and participates in the MSc Epidemiology Postgraduate Programme.
